Gufic BioSciences Share Price

    NSE
    374.60
    +9.30 (2.44%)
    GUFICBIO • 20 Aug, 2025 | 12:57 PM
    Buy
    with MTF at2.50xleverage

    1Y Annualised Return

    3.53%

    3Y Annualised Return

    22.77%

    5Y Annualised Return

    31.71%

    10Y Annualised Return

    28.35%

    The current prices are delayed, login or Open Demat Account for live prices.

    Gufic BioSciences Stock Performance

    1W Return5.05
    1Y Return6.62
    Today's Low361.2
    Prev. Close365.30
    Mkt Cap (Cr.)3,663.14
    1M Return-2.52
    3Y Return87.02
    52-Week High504.25
    Open361.65
    PE Ratio59.91
    6M Return-2.31
    Today's High378.1
    52-Week Low298.8
    Face Value1

    Gufic BioSciences Company background

    Founded in: 1984
    Managing director: Jayesh P Choksi
    Gufic Biosciences Limited is a prominent global pharmaceutical enterprise dedicated to delivering a broad spectrum of pharmaceutical services to its clients. Renowned for its extensive range of pharmaceutical products, Gufic operates as a comprehensive solution provider in both domestic and international markets, supported by a robust distribution network. The Company is ranked among the top 100 pharmaceutical companies in India.Gufic is a leading manufacturer of lyophilized injections in India, with a stateoftheart automated lyophilization plant located in Navsari, Gujarat. The Company was incorporated in July, 1984. The recent addition of the Indore manufacturing facility has further solidified Gufics position as one of the worlds largest producers of lyophilized injections. These products cover therapeutic areas, including antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs).The Company made a reverse merger of itself with Central Finance. The promoters of GBL took over Central Finance at Rs 4042 per share and then got GBL listed on BSE. Presently, the Company is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Choksi and Gandhi family, the promoters of GBL, have a longstanding presence in the pharma industry. In 1960, the family set up a joint venture company called Lyka Labs. In 1976, they decided to part ways and the Choksi family took over the manufacturing facility and the Gufic group of companies was born. Initially known as Gujarat Fine Chemicals, the first foray of the Gufic group was in the manufacture of various bulk drugs. The company later entered the formulation market. Currently, the overall profile of GBL comprises ethical products, herbal products, consumer products and bulk drugs that are sold in the domestic and the international markets. Over the past several years, the company have a known reputation of creating brands that have vaulted to leadership positions in the category in which they have been marketed. To mention a few names: Shapers (sanitary napkins), Onergy, and Stretch nil.In the year 2000, the company issued Bonus Equity Shares in proportion of five Equity shares for every two Equity shares held.Gufic has divested brands in the ethical pharma business in a sellers market. The company plan to invest further in RD activities and aggressively enter the herbal product and consumer product segments, where it foresee a huge potential. While benefiting from the rich, traditional knowledge base in India, it would like to operate from an area of strength in the herbal products segment.In 202021, Gufic Lifesciences Private Limited amalgamated with the Company through the Scheme of Amalgamation which became effective from May 21, 2021. GUFIC UK LIMITED (GUL), a wholly owned subsidiary of the Company, was incorporated in United Kingdom on March 15, 2022. Similarly, in 2023, Gufic Ireland Limited (GIL) was incorporated on March 02, 2023.

    Gufic BioSciences Financial Highlights


    Gufic BioSciences reported a Q1 FY 2025-26 revenue of ₹223.72 crore, up 1.8% YoY, with net profit decreased -19.1% to ₹13.07 crore. For the full year FY20252026, revenue reached ₹823.43 crore and profit touched at ₹69.65 crore. As of Jun '25, Gufic BioSciences’s market capitalisation stood at ₹3,663.14 crores. Shareholding as of Jun '25 shows promoters holding 72.5%, with FIIs at 0.3%, DIIs at 3.4%, and public at 23.8%.

    As of 20 Aug, 2025, Gufic BioSciences share price is ₹374.7. The stock opened at ₹361.6 and had closed at ₹365.3 the previous day. During today’s trading session, Gufic BioSciences share price moved between ₹361.20 and ₹378.10, with an average price for the day of ₹369.65. Over the last 52 weeks, the stock has recorded a low of ₹298.80 and a high of ₹504.25. In terms of performance, Gufic BioSciences share price has declined by 5.9% over the past six months and has increased by 3.53% over the last year.
    Read More
    Gufic BioSciences SIP Return Calculator

    Over the past

    1 year
    3 years
    5 years
    Total Investment of ₹65,00,000
    Would have become ₹66,16,528 (+1.79%)
    Daily SIP of 25,000 would have become 66,16,528 in 1 year with a gain of 1,16,528 (+1.79%)
    View details of Market Depth

    Gufic BioSciences Fundamental

    Market Cap (in crs)

    3,663.14

    Face Value

    1

    Turnover (in lacs)

    1,746.81

    Key Metrics

    Qtr Change %
    25.69% Fall from 52W High
    -4.1
    Dividend yield 1yr %
    0.03

    Gufic BioSciences Key Financials

    View more
    Loading chart...
    Loading chart...
    Loading chart...
    Loading chart...
    Gufic BioSciences Quarterly Revenue
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    223.72 Cr
    205.02 Cr
    207.79 Cr
    204.18 Cr
    202.81 Cr
    Gufic BioSciences Yearly Revenue
    Mar 2025Mar 2024
    823.43 Cr
    808.84 Cr
    Gufic BioSciences Quarterly Net Profit/Loss
    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    13.07 Cr
    7.72 Cr
    19.31 Cr
    21.77 Cr
    20.86 Cr
    Gufic BioSciences Yearly Net Profit/Loss
    Mar 2025Mar 2024
    69.65 Cr
    86.14 Cr

    Gufic BioSciences Result Highlights

    • Gufic BioSciences Ltd reported a 14.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.1%.

    • Its expenses for the quarter were up by 22.9% QoQ and 17.9% YoY.

    • The net profit decreased 34.8% QoQ and decreased 37.3% YoY.

    • The earnings per share (EPS) of Gufic BioSciences Ltd stood at 1.3 during Q1 FY 2025-26.

      Read more

    Data Source: BSE, Company announcements

    The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

    Gufic BioSciences Shareholding Pattern

    Promoter
    72.5%
    Foreign Institutions
    0.3%
    Mutual Funds
    3.4%
    Domestic Institutions
    3.4%
    Public
    23.8%
    Promoter
    72.5%
    Foreign Institutions
    0.3%
    Mutual Funds
    3.4%
    Domestic Institutions
    3.4%
    Public
    23.8%
    Promoter
    72.5%
    Foreign Institutions
    0.3%
    Mutual Funds
    2.9%
    Domestic Institutions
    3%
    Public
    24.2%
    Promoter
    72.5%
    Foreign Institutions
    0.2%
    Mutual Funds
    2.5%
    Domestic Institutions
    2.5%
    Public
    24.8%
    Promoter
    72.5%
    Foreign Institutions
    0.2%
    Mutual Funds
    2.3%
    Domestic Institutions
    2.4%
    Public
    24.9%
    Promoter
    72.5%
    Foreign Institutions
    0.1%
    Mutual Funds
    2.1%
    Domestic Institutions
    2.2%
    Public
    25.2%

    Gufic BioSciences Technical Analysis

    Moving Averages Analysis
    374.60
    Current Price
    Bullish Moving Averages
    15
    Bearish Moving Averages
    1
    5Day EMA
    362.00
    10Day EMA
    364.40
    12Day EMA
    365.40
    20Day EMA
    367.90
    26Day EMA
    368.50
    50Day EMA
    368.40
    100Day EMA
    370.80
    200Day EMA
    374.10
    5Day SMA
    359.40
    10Day SMA
    361.40
    20Day SMA
    375.00
    30Day SMA
    371.50
    50Day SMA
    366.20
    100Day SMA
    363.10
    150Day SMA
    373.80
    200Day SMA
    391.40
    Delivery & Volume
    Loading chart...

    Delivery & Volume

    PeriodCombined Delivery VolumeNSE+BSE Traded Volume
    Day Rs
    14578 Rs
    35565 Rs
    Week Rs
    131418 Rs
    164716 Rs
    Month Rs
    63283 Rs
    89956 Rs
    365.43
    Pivot
    Resistance
    First Resistance
    370.77
    Second Resistance
    376.23
    Third Resistance
    381.57
    Support
    First Support
    359.97
    Second support
    354.63
    Third Support
    349.17
    Relative Strength Index
    47.25
    Money Flow Index
    39.15
    MACD
    -3.05
    MACD Signal
    -0.78
    Average True Range
    13.61
    Average Directional Index
    23.47
    Rate of Change (21)
    -4.97
    Rate of Change (125)
    -10.02
    Name
    Holding Percent
    Motilal Oswal Small Cap Fund
    1.38

    Gufic BioSciences Latest News

    14 AUG 2025 | Thursday

    Gufic Biosciences Ltd - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    14 AUG 2025 | Thursday

    Gufic Biosciences Ltd - 509079 - Announcement under Regulation 30 (LODR)-Newspaper Publication

    13 AUG 2025 | Wednesday

    Gufic Biosciences Ltd - 509079 - Announcement under Regulation 30 (LODR)-Investor Presentation

    View More

    Gufic BioSciences Share Price FAQs

    Gufic BioSciences share price is ₹374.60 in NSE and ₹377.20 in BSE as on 20/8/2025.

    Gufic BioSciences share price in the past 1-year return was 6.61. The Gufic BioSciences share hit a 1-year low of Rs. 298.8 and a 1-year high of Rs. 504.25.

    The market cap of Gufic BioSciences is Rs. 3663.14 Cr. as of 20/8/2025.

    The PE ratios of Gufic BioSciences is 59.91 as of 20/8/2025.

    The PB ratios of Gufic BioSciences is 6.09 as of 20/8/2025

    The Mutual Fund Shareholding in Gufic BioSciences was 3.38% at the end of 20/8/2025.

    You can easily buy Gufic BioSciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

    The 52-week high and low of Gufic BioSciences share price is ₹504.25 and ₹298.8 as of 20/8/2025.

    The earnings per share (EPS) of Gufic BioSciences stood at 1.3 during Q1 FY 2025-26.

    Please be aware that Gufic BioSciences stock prices are subject to continuous fluctuations due to various factors.

    Open Demat Account
    +91 -

    Popular Stocks
    60.17
    +0.58 (+0.97%)
    126.88
    +0.08 (+0.06%)
    690.70
    -9.55 (-1.36%)
    2,395.00
    +6.60 (+0.28%)
    148.65
    -0.26 (-0.17%)
    329.85
    +2.10 (+0.64%)
    161.78
    +2.55 (+1.60%)
    327.60
    +6.15 (+1.91%)
    374.00
    -6.05 (-1.59%)
    391.20
    +2.05 (+0.53%)
    Top Gainers
    1,486.90
    +46.90 (+3.26%)
    2,673.80
    +69.00 (+2.65%)
    3,083.40
    +67.20 (+2.23%)
    341.80
    +6.75 (+2.01%)
    251.78
    +4.82 (+1.95%)
    Top Losers
    616.20
    -10.15 (-1.62%)
    888.85
    -13.45 (-1.49%)
    374.65
    -5.40 (-1.42%)
    690.45
    -9.80 (-1.40%)
    1,955.10
    -17.10 (-0.87%)
    Open Demat Account
    +91 -